Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Long-Sought Drug Candidate Can Halt Tumor Growth

August 12, 2014 2:50 pm | News | Comments

It’s a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable." Read more...   

TOPICS:

Clinical Trial Evaluates Safety of Stem Cell Transplantation in Spine

August 12, 2014 2:41 pm | Videos | Comments

Researchers have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries. This Phase 1 clinical trial is recruiting eight patients for the five-year study. Read more...

TOPICS:

Ebola: Questions, Answers About Unproven Drug

August 12, 2014 2:25 pm | by Lauran Neergaard, AP Medical Writer | News | Comments

An experimental Ebola drug has been used to treat two American aid workers and a Spanish missionary priest, and the Liberian government said that it will receive doses of the drug to treat two doctors in the country. Read more...       

TOPICS:
Advertisement

Cortendo Enrolls First Patient into Cushing’s Study

August 12, 2014 11:43 am | News | Comments

Cortendo AB announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., “Study of NormoCort in Cushing’s Syndrome,” after successfully completing its European Investigator meeting supporting SONICS. Read more...

TOPICS:

Prosensa, CureDuchenne Strengthen Collaboration

August 12, 2014 11:38 am | News | Comments

Prosensa Holding N.V. announced that an affiliate of CureDuchenne will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. Read more...

TOPICS:

Sanofi Launches Generic Eloxatin

August 12, 2014 11:31 am | News | Comments

Sanofi US announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop US, the company's generics division. Sanofi's authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent. Read more...

TOPICS:

23andMe, Pfizer Collaborate on Genetics of IBD

August 12, 2014 11:24 am | News | Comments

23andMe announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Read more...

TOPICS:

Bioengineers Create 3-D Brain-Like Tissue

August 12, 2014 11:17 am | News | Comments

Bioengineers have created three-dimensional brain-like tissue that functions like and has structural features similar to tissue in the rat brain, can be kept alive in the lab for more than two months and could provide a superior model for studying normal brain function as well as injury and disease. Read more...

TOPICS:
Advertisement

Liberian Doctors to Get Experimental Ebola Drug

August 12, 2014 11:02 am | by Jonathan Paye-Layleh, Maria Cheng, Associated Press | News | Comments

Liberia announced Monday that it would soon receive doses of an experimental Ebola drug and give it to two sick doctors, making them the first Africans to receive some of the scarce treatment in a spiraling outbreak, which has claimed the lives of 1,013 people in West Africa. Read more...

TOPICS:

Intercept Liver Drug Excels in Trial

August 12, 2014 9:21 am | News | Comments

Shares of Intercept Pharmaceuticals Inc. soared in premarket trading Tuesday, a day after the drug developer said its most advanced candidate performed better than a placebo in a mid-stage study of patients with a form of chronic liver disease. Read more...

TOPICS:

Mirati Lymphoma Drug Designated Orphan Drug

August 11, 2014 3:03 pm | News | Comments

Mirati Therapeutics Inc. announced that the U.S. FDA has granted Orphan Drug Designation - which provides seven years of market exclusivity - to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). Read more...

TOPICS:

European Commission Approves Macular Edema Drug

August 11, 2014 2:54 pm | News | Comments

Regeneron Pharmaceuticals Inc. announced that Eylea (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema, the leading cause of vision loss in working-age adults in much of the developed world. Read more...

TOPICS:

Regulators Approve Glioblastoma Study Enhancements

August 11, 2014 2:46 pm | News | Comments

Northwest Biotherapeutics announced that, following a 9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing Phase 3 clinical trial of DCVax-L Glioblastoma multiforme (GBM) brain cancer. Read more...

TOPICS:

Discovery May Provide Key to Treating CHF

August 11, 2014 2:38 pm | News | Comments

Researchers have discovered a previously unknown cardiac molecule -- a long non-coding RNA called myosin heavy-chain-associated RNA transcript or Myheart  -- that could provide a key to treating, and preventing, heart failure. Read more...

TOPICS:

First US Ebola Outbreak Stopped 25 Years Ago

August 11, 2014 2:24 pm | by Matthew Barakat, Associated Press | News | Comments

It had all the makings of a public-health horror story: an outbreak of a wildly deadly virus on the doorstep of the nation's capital, with dozens of lab monkeys dead, multiple people testing positive, and no precedent in this country on how to contain it. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading